Home News Serum Pauses India COVID-19 Vaccine Trials for Now

Serum Pauses India COVID-19 Vaccine Trials for Now

Serum Pauses India COVID-19 Vaccine Trials for Now

Following a scathing show-cause notice from the drug regulator of India, the Serum Institute of India has paused Covid-19 vaccine trials being conducted across 17 different sites till further instructions from the Drug Controller General of India (DCGI). In a statement today, the vaccine maker told BusinessToday. In that, it is pausing COVID-19 trials in India for now. “We are following DCGI’s instructions…we are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” it said.

The SII decision came a day after the DCGI issued a show-cause notice to the vaccine maker for not informing it about AstraZeneca suspending the clinical trials of the Oxford vaccine candidate in other countries, and also for not submitting casualty analysis of the “reported serious adverse events”. The British-Swedish biopharmaceutical major AstraZeneca put a pause on the COVID-19 trials after a UK patient-reported illness.

A Director-General of Health Services notice, accessed by BusinessToday.In, says the “Serum Institute of India, Pune, up till (now) has not informed the central licensing authority regarding pausing the clinical trial carried out by AstraZeneca in other countries and also not submitted casualty analysis of the reported serious adverse event with the investigational vaccine for the contribution of Phase II/III clinical trial of the subject vaccine in the country in light of the safety concerns.”

Notably, the Oxford vaccine was described by the World Health Organisation (WHO) as the world’s leading candidate and the most advanced in terms of development. Pausing of trials could delay the vaccine development process as Serum Institute is the frontrunner when it comes to companies producing COVID-19 vaccines in India. India, which is now the second most affected country after the US in terms of COVID-19, registered a record single-day spike of 95,735 COVID-19 cases and 1,172 fatalities in one day, taking the country’s caseload past 44 lakh, and death toll to 75,062, the latest government data suggests.

Regarding the show-cause notice issued by the DCGI, Serum Institute of India had earlier said that it would follow the DCGI directions on the matter. “If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols,” it had added.

After UK pharma major AstraZeneca put a pause on the COVID-19 trials on Wednesday, Serum Institute CEO Adar Poonawalla told BusinessToday. In that trial in India had not been stopped. “The Indian trials have not been stopped yet…and there’s nothing to worry about. It’s some unrelated issue that happened… neurological issue with a patient in the UK and we have to wait for AstraZeneca to explain what happened there but this is not vaccine-related. So, nothing to really worry about, and the India trials are also going on, that has not been stopped,” Poonawalla said.

The company had started trials among 1,600 volunteers at 17 centers, each with about 100 volunteers, on August 22. However, SII had declined to confirm the time when the vaccine will be available in the market.

Earlier, an AstraZeneca spokesperson had described the pause as a “routine action”, which must be done as part of the process in case of an “unexplained illness” in any of the participants. The company did not explain the nature of the illness. A New York Times report, however, attributed a person familiar with trials saying that one UK participant had ‘transverse myelitis’, an inflammation of the spinal cord which is normally caused by viral infections. It’s not clear yet if this was in direct response to the vaccine.

Meanwhile, the Serum Institute has promised to provide 400 million doses to low-and middle-income countries by 2020, and 1 billion doses in total. It aims to make over 6 crore doses per month of its vaccine candidate, which will be increased to 10 crores per month by April 2021.

Eskalera, a Startup Led by Goldman Sachs’ Former HR Head Has Launched a Diversity and Inclusion Index

Eskalera, a technology startup led by Goldman Sachs former human resources head Dane Holmes, has launched an index to measure corporate diversity and inclusiveness,...

HSBC to Remove 35,000 Jobs Amidst Covid-19 Crises

HSBC Holdings Plc has restarted cutting as many as 35,000 jobs, three months after the coronavirus outbreak forced it to pause a long-awaited overhaul...

Genpact Offers Its Internal Skill Training Program Globally for Everyone

Genpact has announced Adapt and Rise, a role-based online learning platform that leverages Genpact's expertise honed from delivering real-world change for hundreds of clients....

San-Francisco Based Learning Platform Degreed Has Raised $32 Million in New Funding

The upskilling platform, Degreed, has announced $32 million in new funding in direct response to overwhelming demand for better skill insights, talent mobility, and...

Research Shows the Implications of Workplace Layouts on Employee Productivity and Overall Performance

As some workplaces prepare for the gradual return of employees and overhaul office layouts and seating plans, research has shown this could also have...

Employee Concierge ‘Back Technologies’ Integrates Automation Into Internal HR and Other Support Tasks

Companies are under increasing pressure to automate workflows and digitally service their employees, particularly in light of trends toward remote work. It takes an...

HR Strategies to Help Your Business Navigate the New ‘Normal’

No business is immune to the massive changes resulting from the health crisis. Organizations have proven themselves to be agile, and employees have demonstrated...

The Importance Of Diversity And Inclusion In HR, Hiring, Talent Management: Thoughts From A Top Expert

Michael C. Hyter is one of today’s best-known experts on inclusion and diversity and the author of The Power of Choice: Embracing Efficacy to Drive Your Career and The...

HR Expert Highlights Actionable Steps to ‘Make Real Change’ Against Racism in Your Workplace

Kyra Leigh Sutton, Ph.D., is a faculty member at the Rutgers University School of Management and Labor Relations, where she teaches human resources courses...

Adidas Employees Want Company to Investigate HR Chief for Response to Racial Issues

A group of Adidas employees from around the globe is asking the company to investigate its chief human resources officer, as part of a...